Leading Biotech Giants Set Up Shop In China
This article was originally published in PharmAsia News
Executive Summary
Two of the world's leading biotech companies, Biogen Idec and Genzyme, set up branch offices in Shanghai last year. Even as their licensing revenue from multinational pharmaceutical corporations increases, these biotech firms have decided to enter the Chinese market to build up their own sales and distribution networks. Biogen Idec will be investing heavily in China over the next five years while Genzyme plans to set up a plant in Beijing. (Click here for more)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.